The goal of the Onco-Imaging & Biotechnology (OIB) program is to develop and assess quantitative systems and technologies that improve detection, clinical management, and quality of life for cancer patients. OIB is strongly interdisciplinary, integrating basic scientists with technologists and clinicians.
Research in OIB is focused around three key themes, each of which includes basic science, technology development, and translational research activities spanning from animal models to human subjects in various malignancies, including cancers of the breast, skin, GI, oral cavity, prostate, and brain. In addition, OIB members also apply emerging technologies in multi-center and cooperative group clinical trials in order to standardize and validate methods and endpoints for improved cancer detection and clinical management.
OIB research themes are:
Many of these technologies are custom-designed and fabricated within the Laser Microbeam and Medical Program (LAMMP) and the Laboratory for Fluorescence Dynamics (LFD), NIH P41 Biomedical Technology Centers in the Beckman Laser Institute and the Department of Biomedical Engineering. These technologies include a broad range of non-linear optical microscopies (e.g. Raman, Fluorescence, and Harmonic generation techniques), Laser Microbeams, Optical Coherence Tomography, Acousto-Optic Imaging and Elastography, Laser Speckle Imaging, Spatial Frequency Domain Imaging, and Diffuse Optical Spectroscopy and Imaging.
We develop and validate multi-modality imaging and spectroscopy technologies combining various approaches such as MRI-Optics, MRI-Nuclear, and X-Ray/CT platforms. The goal of multi-modality devices is to combine anatomical landmarks with molecular signatures for improved detection, determination, and prediction of therapeutic response.
We test nano- and microfluidic technologies and integrated “lab-on-a-chip” and “body-on-a-chip” systems to advance cellular and molecular diagnostics for improved cancer detection and therapy. Importantly, the new technologies and methods for engineering cellular systems we are developing are optimized such that their integration into multi-system platforms allows visualization using many of the technologies described above. These allow us to examine the complex dynamics between cells, vasculature and extracellular matrix. These in vitro engineered tissues are used to advance our understanding of the disease process and as a test bed to determine response to therapy.
Further, OIB leadership works to leverage these technologies to improve cancer detection, clinical management and patient quality of life, specifically by:
Chen, Jeon Hor
Kwon, Young Jik
Su, Min-ying (Lydia)